Skip to content

    Bladder Cancer Health Center

    Medical Reference Related to Bladder Cancer

    1. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Stage I Bladder Cancer Treatment

      Standard Treatment Options for Stage I Bladder CancerPatients with stage I bladder tumors are unlikely to die from bladder cancer, but the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors who were followed for a minimum of 20 years or until death, the risk of bladder recurrence after initial resection was 80%.[1] Of greater concern than recurrence is the risk of progression to muscle-invasive, locally-advanced, or metastatic bladder cancer. While progression is rare for low-grade tumors, it is common among high-grade cancers. One series of 125 patients with TaG3 cancers followed for 15 to 20 years reported that 39% progressed to more advanced stage disease, while 26% died of urothelial cancer. In comparison, among 23 patients with TaG1 tumors, none died and only 5% progressed.[2] Risk factors for recurrence and progression include the following:[2,3,4,5,6]High-grade disease.Presence of carcinoma in situ.Tumor larger

    2. Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Questions or Comments About This Summary

      If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

    3. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (10 / 23 / 2014)

      The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.This summary was comprehensively reviewed and reformatted.This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

    4. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Bladder Cancer

      For more information from the National Cancer Institute about bladder cancer, see the following:Bladder Cancer Home PageWhat You Need to Know About™ Bladder CancerBladder and Other Urothelial Cancers ScreeningUnusual Cancers of ChildhoodDrugs Approved for Bladder CancerBiological Therapies for CancerSmoking Home Page (Includes help with quitting)For general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates

    5. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Bladder Cancer

      Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. The bladder is a hollow organ in the lower part of the abdomen. It is shaped like a small balloon and has a muscular wall that allows it to get larger or smaller. The bladder stores urine until it is passed out of the body. Urine is the liquid waste that is made by the kidneys when they clean the

    6. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Urethral Cancer Associated With Invasive Bladder Cancer

      Approximately 10% (range, 4%–17%) of patients who undergo cystectomy for bladder cancer can be expected to have or to later develop clinical neoplasm of the urethra distal to the urogenital diaphragm. Factors associated with the risk of urethral recurrence after cystectomy include:[1,2]Tumor multiplicity.Papillary pattern.Carcinoma in situ.Tumor location at the bladder neck.Prostatic urethral mucosal or stromal involvement.The benefits of urethrectomy at the time of cystectomy need to be weighed against the morbidity factors, which include added operating time, hemorrhage, and the potential for perineal hernia. Tumors found incidentally on pathologic examination are much more likely to be superficial or in situ in contrast to those that present with clinical symptoms at a later date when the likelihood of invasion within the corporal bodies is high. The former lesions are often curable, and the latter are only rarely so. Indications for urethrectomy in continuity with

    7. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Overview

      This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about Bladder and Other Urothelial Cancers screening.

    8. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Stage 0 Bladder Cancer Treatment

      Standard Treatment Options for Stage 0 Bladder CancerPatients with stage 0 bladder tumors can be cured by a variety of treatments, even though the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors who were followed for a minimum of 20 years or until death, the risk of bladder cancer recurrence after initial resection was 80%.[1] Of greater concern than recurrence is the risk of progression to muscle-invasive, locally-advanced, or metastatic bladder cancer. While progression is rare for patients with low-grade tumors, it is common among patients with high-grade cancers. One series of 125 patients with TaG3 cancers followed for 15 to 20 years reported that 39% progressed to more advanced-stage disease while 26% died of urothelial cancer. In comparison, among 23 patients with TaG1 tumors, none died and only 5% progressed.[2] Risk factors for recurrence and progression are the following:[2,3,4,5,6]High-grade disease.Presence of

    9. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Urethral Cancer

      Incidence and MortalityUrethral cancer is rare. The annual incidence rates in the Surveillance, Epidemiology, and End Results database over the period from 1973 to 2002 in the United States for men and for women were 4.3 and 1.5 per million, respectively, with downward trends over the three decades.[1] The incidence was twice as high in African Americans as in whites (5 million vs. 2.5 per million). Urethral cancers appear to be associated with infection with human papillomavirus (HPV), particularly HPV16, a strain of HPV known to be causative for cervical cancer.[2,3]Because of its rarity, nearly all information about the treatment of urethral cancer and the outcomes of therapy is derived from retrospective, single-center case series and, therefore, represents a very low level of evidence of 3iiiDiv. The majority of information comes from cases accumulated over many decades at major academic centers.AnatomyThe female urethra is largely contained within the anterior vaginal wall. In

    10. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Stage Information for Urethral Cancer

      Prognosis and treatment decisions are both determined by:[1]The anatomical location of the primary tumor.The size of the tumor.The stage of the cancer.The depth of invasion of the tumor.The histology of the primary tumor is of less importance in estimating response to therapy and survival.[2] Endoscopic examination, urethrography, and magnetic resonance imaging are useful in determining the local extent of the tumor.[3,4]Distal Urethral CancerThese lesions are often superficial. Female: Lesions of the distal third of the urethra.Male: Anterior, or penile, portion of the urethra, including the meatus and pendulous urethra.Proximal Urethral CancerThese lesions are often deeply invasive. Female: Lesions not clearly limited to the distal third of the urethra.Male: Bulbomembranous and prostatic urethra.Urethral Cancer Associated with Invasive Bladder CancerApproximately 5% to 10% of men with cystectomy for bladder cancer may have or may develop urethral cancer distal to the urogenital

    Displaying 1 - 10 of 65 Articles Page 1 2 3 4 5 6 7 Next >>

    Today on WebMD

    bladder cancer x-ray
    Do you know the warning signs?
    man with a doctor
    Our health check will steer you in the right direction.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Lifestyle Tips for Depression Slideshow
    SLIDESHOW
    Bladder Sparing Cancer Treatment
    VIDEO
     
    Vitamin D
    SLIDESHOW
    Pets Improve Your Health
    SLIDESHOW